We maintain our Buy rating on Abbott India (AIL) and revise the TP to Rs7,530 (earlier TP Rs7,030) based on 24x March'20 EPS of Rs313.6. AIL's EBIDTA for Q4FY18 was lower than our expectations whereas net profit was higher than our expectations. The pharma major's revenue grew 10% YoY, margin improved 470bps to 13.5% and net profit grew 138% YoY. That said, the company's eleven leading brands grew faster than the market and are likely to drive future growth. We expect margins to improve post the launch of new products and with the company's entry into the high-margin vaccine segment. AIL is a debt-free cash...